NEW YORK (GenomeWeb News) — Pharmaceutical companies this year will rely on pharmacogenomic technologies to offset rising drug-development costs, loss of patent exclusivity, and a tight reimbursement environment, according to the Tufts Center for the Study of Drug Development.
“Drug developers will work to validate safety and efficacy biomarkers, develop predictive preclinical toxicology screens, utilize micro-dosing studies, and expand
pharmacogenomic programs to improve success rates,” according to an annual outlook report.
The report projects that “drug companies will strive to speed development and reduce failure rates” through “greater use of new technologies,” including pharmacogenomic tools.
“Despite a growing list of challenges facing drug developers … there is reason for optimism,” according to the report.
The report, which can be found here, predicts that drug developers will be compelled “to improve the way they manage risk, especially as they seek to lower late-stage development attrition rates, and to increase their utilization of information technology.”
In another nod to pharmacogenomics, the outlook said that these challenges will “encourage sponsors to make greater use of innovative practices, such as clinical trial enhancement, to improve R&D performance and output.”
Pharmaceutical companies will also continue to “grapple with the complex economics” of developing drugs for subgroups, “including whether to internalize development of diagnostic markers that can be linked to therapeutics,” the study said.
Drug companies “are improving their management of risk, especially by actively lowering late-stage attrition rates through greater use of information technology and other development practices,” Tufts CSDD Director Ken Kaitin said in a statement accompanying the report.